Oral Health Status in Children With β-Thalassemia Major

May 25, 2026 updated by: Mariam Mohamed Mohamed Diaa eldin Shafie, Cairo University

Effectiveness of a Structured Oral Health Educational Program on Oral Hygiene and Oral Health Related Quality of Life in Children With β-Thalassemia Major: Before and After Interventional Study.

To evaluate the effectiveness of a structured oral health educational program on oral hygiene status and oral health-related quality of life (OHRQoL) among children diagnosed with β-thalassemia.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Not yet recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Benefits to the patient

  • The clinical examination and OHRQoL assessments provide a well-established foundation to plan the oral-dental treatment for each individual.
  • Improved awareness among β-thalassemia patients and caregivers regarding oral hygiene practices and the importance of regular dental visits may contribute to better oral health outcomes and enhanced overall quality of life.

Benefits to the community

  • Provide valuable epidemiological data on the oral health status and oral health-related quality of life in children with β-thalassemia.
  • Assist dental professionals, healthcare providers, and policymakers in planning targeted preventive strategies and integrating oral health care into the comprehensive management of thalassemia.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
45

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Children having medical records confirmed of β-thalassemia diagnosis.
  • Age range between 8-10 years old.
  • Have acceptable cooperation

Exclusion Criteria:

  • Children with Cognitive impairment.
  • Participants in another oral health education program or clinical study within the past 6 months will be excluded.
  • Unstable clinical condition as judged by the treating physician

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: an Immediate Intervention Group
oral health educational program will be given to this group of patients
Other: oral health educational program for Immediate Intervention Group

Oral Health Educational Program

Educational Content (Oral health educational session) including:

  • Interactive lectures with visual aids and video demonstration
  • Correct Tooth brushing technique
  • Frequency & time of brushing
  • How to use mouth rinse and toothpaste
  • How to properly use the dental floss

Teaching Methods

  • Demonstration on dental models
  • Hands-on supervised brushing
  • Use of disclosing agents

Motivational Interviewing

  • Caregiver's guide booklet
  • Dietary counseling
  • Importance of mouth rinse and fluoridated tooth pastes

Materials Used

  • Ultra soft Toothbrushes
  • Alcohol-free mouth rinse
  • Use of fluoridated toothpaste
  • Interdental floss
  • Oral health promotion leaflet
Placebo Comparator: Waitlist Control Group
routine oral hygiene instructions will be given to this group of children
Other: routine oral hygiene instructions
Use toothbrush and toothpaste for oral hygiene Brush twice daily Regular dental checkups Keep toothbrush clean

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Oral Hygiene
Time Frame: Baseline Measurement and After 1,3 and 6 months

Oral Hygiene Index-Simplified (OHI-S)

Minimum value: 0

Maximum value: 6

Interpretation of scores:

Higher scores indicate worse oral hygiene (greater debris and calculus accumulation).

Lower scores indicate better oral hygiene.
Baseline Measurement and After 1,3 and 6 months

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Oral Health Related Quality Of Life (OHRQoL)
Time Frame: Baseline and after 1,3 and 6 months

Measured using Child Perception Questionnaire (children aged 8-10 years) Child Perceptions Questionnaire for children aged 8-10 years (CPQ8-10)

Minimum value: 0

Maximum value: 100

Interpretation of scores:

Higher scores indicate a worse oral health-related quality of life (greater negative impact on the child's well-being).

Lower scores indicate a better oral health-related quality of life.
Baseline and after 1,3 and 6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Cairo University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

  • Abbas, F., Tabesh, A., Yavari, A., Makaremi, R., Bizhani, O. and Mahmood, M. (2023) 'Evaluation and relation of oral health-related quality of life and oral health status in Thalassemia Major patients, a cross-sectional study', BMC Oral Health, 23(493), pp. 1-9. Available at: doi.org. Al-Blaihed, D., El-Housseiny, A.A., Farsi, N.J. and Farsi, N.M. (2020) 'Validity and reliability of the Arabic version of the child perceptions questionnaire for 8-10-year-old children', Quality of Life Research, 29(11), pp. 3119-3125. Available at: https://doi.org/10.1007/s11136-020-02545-y. Amirabadi, F., Saravani, S., Miri-Aliabad, G., Khorashadi-Zadeh, M. (2019). 'The Association between Dental Health Status and Oral Health-Related Quality of Life of Children Diagnosed with β-Thalassemia Major in Zahedan City, Iran', Journal of Pediatric Perspectives, 7(2), pp. 8985-8991. doi: 10.22038/ijp.2018.34517.3034 Barriault, S., Deneault, A.-A., Kempe, S., Madigan, S., Lovegrove, A., Dimitropoulos, G., Pillai Riddell, R. and Racine, N. (2019) 'A randomized waitlist control trial of the Make the Connection® online program for caregivers of infants and young children: Study protocol', BMC Pediatrics, 19, p. 176. https://doi.org/10.1186/s12887-019-1567-2 Desveaux, L., Agarwal, P., Shaw, J., Hensel, J.M., Mukerji, G., Onabajo, N., Marani, H., Jamieson, T., Bhattacharyya, O., Martin, D., Mamdani, M., Jeffs, L., Wodchis, W.P., Ivers, N.M. and Bhatia, R.S. (2018) 'A randomized wait-list control trial to evaluate the impact of a mobile application to improve self-management of individuals with type 2 diabetes: a study protocol', BMC Medical Informatics and Decision Making, 18, Article 49. https://doi.org/10.1186/s12911-018-0613-5 El-Kamah, G., Adam, S., Magdy, P., Michel, M. and Afifi, H. (2014) 'Quality of life outcomes among Egyptian children with beta-thalassemia', Blood, 124(21), p. 4864. Fadel, H.T., Zolaly, M.A., Alharbi, M.O., Qarah, L.A., Alrehili, M.S., Alamri, A.D. and Tarawah, A.M. (2

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
November 1, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
November 1, 2027

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 1, 2027

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
May 18, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 25, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
May 29, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
May 29, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 25, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
May 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • OHRQOL in β-TM children

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings